Date printed: 21/02/2019
Priorix
Details for Priorix vaccine and its components.
Sponsor:
GlaxoSmithKline Australia
Administration route:
Intramuscular injection, Subcutaneous injection
Vaccine group:
Combination vaccines
Registered for use in people aged ≥12 months.
MMR — measles-mumps-rubella combination vaccine
Lyophilised pellet in a monodose vial with a pre-filled diluent syringe.
Each 0.5 mL reconstituted dose contains:
- ≥103.0 cell culture infectious dose 50% (CCID50) of live attenuated measles virus (Schwarz strain)
- ≥103.7 CCID50 of live attenuated mumps virus (RIT 4385 strain, derived from the Jeryl Lynn strain)
- ≥103.0 CCID50 of live attenuated rubella virus (Wistar RA 27/3 strain)
- lactose
- neomycin
- sorbitol
- mannitol
The product information and consumer medicine information for Priorix have more details.
Page history
Last updated:
4 June 2018
Last reviewed:
4 June 2018
Definitions
- MMR
- measles-mumps-rubella
This document was printed on: 23/02/2019. Printed content may be out of date. For up to date information, always refer to the digital version: https://immunisationhandbook.health.gov.au/vaccines/priorix.